chondroitin-sulfates and Bacterial-Infections

Glycosaminoglycan hyaluronic acid (HA) and chondroitin sulphate (CS) protect the urothelium. Damage to the urothelium may increase bacterial adherence and infection risk. This meta-analysis evaluated the effect of intravesical HA and HA and CS (HA-CS) combination therapy in recurrent bacterial cystitis (RBC) in adult women.. A systematic literature search was performed. Primary outcomes were urinary tract infection (UTI) rate per patient-year, and UTI recurrence time (days). Secondary outcomes were 3-day voids and Pelvic Pain and Urgency/Frequency (PUF) symptom scale total score.. Four studies involving a total of 143 patients were retrieved and assessed in this analysis. Two were randomized, and two were nonrandomized. A significantly decreased UTI rate per patient-year [mean difference (MD) -3.41, 95 % confidence interval (CI) -4.33 to -2.49, p < 0.00001) was found. Similarly, pooled analysis showed a significantly longer mean UTI recurrence time (days) using either HA or HA-CS therapy (MD 187.35, 95 % CI 94.33-280.37, p < 0.0001). Two studies using HA and HA-CS therapy reported outcomes on 3-day voids, which were not significantly improved after therapy (MD -3.59, 95 % CI -8.43-1.25, p = 0.15), but a significantly better PUF total score (MD -7.17, 95 % CI -9.86 to -4.48, p < 0.00001) was detected in HA-CS groups.. Intravesical HA and HA-CS in combination significantly reduced cystitis recurrence, mean UTI recurrence time, and PUF total score. Study limitations include the small number of patients and possible bias. Further studies are needed to validate this promising treatment modality.

Topics: Administration, Intravesical; Bacterial Infections; Chondroitin Sulfates; Cystitis; Female; Humans; Hyaluronic Acid; Secondary Prevention; Viscosupplements

Cystic fibrosis (CF) is associated with mutation and abnormal function of the cystic fibrosis transmembrane conductance regulator (CFTR) that affects cellular chloride transport. Clinically, CF of the lung is associated with excessive accumulation of secretions, including the sulfated glycosaminoglycans, chondroitin sulfate and dermatan sulfate (DS), both of which contain sulfated N-acetylgalactosamine residues. The sulfatase enzymes, which are a highly conserved group of enzymes with high specificity for designated sulfate groups, include arylsulfatase B, a lysosomal enzyme. Arylsulfatase B, also known as N-acetyl galactosamine 4-sulfatase, can degrade DS and chondroitin-4 sulfate. Previously reported data demonstrated diminished activity of arylsulfatase B in lymphoid cell lines of patients with CF compared to normal control subjects. Frequent infections with Pseudomonas, a sulfatase-producing organism, occur in patients with CF, whereas infections with Mycobacterium tuberculosis, which lacks sulfatase activity, are infrequent. Additional investigation to determine if diminished function of arylsulfatase B is a consistent finding in cells of patients with CF may be informative, and may help to correlate the molecular, biochemical, and clinical characteristics of CF.

Topics: Bacterial Infections; Chondroitin Sulfates; Cystic Fibrosis; Dermatan Sulfate; Glycosaminoglycans; Humans; Ion Exchange; Lung; Mucopolysaccharidosis VI; N-Acetylgalactosamine-4-Sulfatase; Pseudomonas Infections; Sodium; Sulfates; Tuberculosis

The glycosaminoglycan hyaluronic acid (HA) protects the urothelium; damage may increase bacterial adherence and infection risk. This study evaluated the effect of intravesical HA in recurrent bacterial cystitis (RBC).. Women with RBC were randomized to intravesical HA 800 mg and chondroitin sulfate (CS) 1 g (IALURIL, IBSA) in 50 mL of saline solution once weekly for 4 weeks then once every 2 weeks twice more (group 1) or long term antibiotic prophylaxis using sulfamethoxazole 200 mg and trimethoprim 40 mg once weekly for 6 weeks (group 2; control). Evaluations included: cystitis recurrence at 2 and 12 months; subjective pain symptoms (visual analog scale [VAS]); 3 day voiding; sexual function; quality of life (King's Health Questionnaire [KHQ]); frequency symptoms/frequency symptoms (PUF symptom scale); and maximum cystometric capacity (MCC). Means ± standard deviations were reported, with Mann-Whitney test for between-group comparison (significance P < .05).. Of 28 women (mean age 60 ± 13 y) randomized, 26 completed follow-up (mean follow-up 11.5 mo). Group 1 showed a significant improvement in all evaluations; cystitis recurrence (1 ± 1.2 versus 2.3 ± 1.4, P = .02); 3-day voiding (mean 17.8 ± 3.5 vs 24.2 ± 8.3, P = .04); symptom VAS (1.6 ± 0.8 vs 7.8 ± 1.6, P < .001); PUF score (11.2 ± 2.7 vs 19.6 ± 2.2, P < .001), KHQ score (18.4 ± 7.2 vs 47.3 ± 13.6, P < .001), and MCC (380 ± 78 vs 229 ± 51 mL, P < .001) vs group 2 at 12 mo. No adverse effects were recorded.. Intravesical HA and CS in combination significantly reduced cystitis recurrence and improved urinary symptoms, quality of life, and cystometric capacity in RBC patients at 12 mo follow-up versus antibiotic prophylaxis. Study limitations include a small sample and relatively short follow-up.

Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Bacterial Infections; Chondroitin Sulfates; Cystitis; Drug Therapy, Combination; Female; Humans; Hyaluronic Acid; Middle Aged; Pain Measurement; Quality of Life; Recurrence

Poly (l-lactide)-graft-chondroitin sulfate (PLLA-g-CS) copolymers were synthesized with different l-lactide contents via ring-opening polymerization. Chemical structure of the synthesized copolymers was confirmed by FTIR and HNMR analyses. The degree of polymerization and substitution of PLLA was found to be 0.56 and 2.98, respectively. Nisin was loaded in PLLA-g-CS nanogels at 37 and 42 °C. The hydrodynamic radius of the nanogels was 181 and 399 nm, respectively. The release profile was studied at two different temperatures and pHs over 7 days. The results indicated a variation of the cumulative release of nisin from 25 to 98% depending on the pH and temperature of release media. Cytotoxicity test of nisin loaded nanogels on human dermis fibroblast cells, confirmed no toxic effect. Finally, Antimicrobial activity of the nanogel was evaluated against Staphylococcus aureus and Escherichia coli bacteria. Overall, this study indicated that the dual responsive nanocarrier could potentially be used for infection therapeutic applications.

Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacterial Infections; Cell Survival; Chondroitin Sulfates; Doxorubicin; Drug Carriers; Escherichia coli; Fibroblasts; HeLa Cells; Humans; Nanogels; Nanoparticles; Polyethylene Glycols; Polyethyleneimine; Staphylococcus aureus; Temperature

The attachment of a variety of

Topics: Bacterial Infections; Bacterial Proteins; Cell Line, Tumor; Chondroitin Sulfates; Glycosaminoglycans; HeLa Cells; Heparitin Sulfate; Humans; Ligands; Ligilactobacillus salivarius; Protein Biosynthesis; Proteoglycans; Transcription, Genetic

In this study, we evaluated the utility of a dermal substitute for preserving maximal foot length after urgent surgical debridement. Patients referred to our Diabetic Foot Center with foot lesions were assessed for sensory-motor neuropathy, infection and critical limb ischaemia. The presence of acute foot infection indicated the need for immediate surgical debridement. The degree of amputation, if necessary, was based on the amount of apparently non infected vital tissue. When vital tendon/bone tissue remained exposed, the lesion was covered with a dermal substitute. From January to December 2008, 393 patients underwent surgical treatment for diabetic foot syndrome; 30 patients underwent immediate surgical debridement resulting in exposed tendon and/or bone tissues. An average of 4.4 +/- 2.1 days following surgical debridement, all 30 patients underwent dermal regeneration template grafting to cover-exposed healthy tendon and bone tissues, instead of achieving primary wound closure with a proximal amputation. After 21 days, a skin graft was performed. Complete wound healing occurred in 26 patients (86.7%). In these patients, the amputation level was significantly more distal (P < 0.003) with respect to that potentially required for immediate wound closure. The average healing time was 74.1 +/- 28.9 days. Four patients underwent a more proximal amputation. No patients underwent major amputation. The use of the dermal substitute for treating exposed tendon and bone tissues allowed timely wound healing and preserved maximal foot length. Continued follow-up will allow assessment of long-term relapse and complication rates. Such treatment could constitute part of the comprehensive management of diabetic wounds.

Topics: Acute Disease; Aged; Amputation, Surgical; Bacterial Infections; Chi-Square Distribution; Chondroitin Sulfates; Collagen; Debridement; Diabetic Foot; Emergencies; Female; Humans; Male; Retrospective Studies; Shoes; Skin Transplantation; Time Factors; Treatment Outcome; Wound Healing; Wound Infection

Endogenous heparinoids impair coagulation, evidenced by thrombelastography in cirrhotic patients with bacterial infection, but it is not clear which glycosaminoglycans can be detected by native and heparinase-modified thrombelastography. To assess the effects of different glycosaminoglycans on thrombelastography parameters and the reversibility of these effects by heparinase-I-modified thrombelastography. Twenty volunteers were enrolled. Solutions of heparan sulphate, dermatan sulphate, and chondroitin-4-sulphate were prepared at 'equivalent' concentrations, based on the composition and anticoagulant activity of danaparoid. Serial dilutions of each glycosaminoglycan were prepared to achieve 1.0, 0.5, 0.1, and 0.05 U/ml. Native and heparinase-modified thrombelastography, anti-activated factor X activity and heparin cofactor II activity were evaluated at each concentration. A statistically significant heparin-like effect was seen with 1 and 0.5 U/ml heparan sulphate, and 1 and 0.5 U/ml dermatan sulphate, which was completely reversed by heparinase-modified thrombelastography. Anti-activated factor X activity was significantly increased in samples containing heparan and dermatan sulphates. The heparin cofactor II activity decreased with 1.0 and 0.5 U/ml dermatan sulphate and chondroitin-4-sulphate, but not with heparan sulphate. Heparan and dermatan sulphates affect haemostasis when added to whole blood in vitro, detectable by native thrombelastography and completely reversed by heparinase-I-modified thrombelastography. They may therefore be responsible for the heparin-like effect seen by thrombelastography in patients with cirrhosis and bacterial infection.

Topics: Bacterial Infections; Blood Coagulation; Chondroitin Sulfates; Dermatan Sulfate; Fibrosis; Glycosaminoglycans; Heparin Cofactor II; Heparin Lyase; Humans; Thrombelastography

A bilayer "artificial skin" composed of an outer layer of silicone and an inner sponge layer of collagen and chondroitin sulphate has been developed by modifying the technique proposed by Yannas et al. (1980). Following experimental successes, the "artificial skin" was applied clinically. It was placed on the skin defects of 10 patients. Three weeks after application the outer layer of silicone sheet was peeled off and thin split thickness skin was grafted onto the newly synthesised dermis-like tissue. Secondary skin grafts took perfectly in all cases and postoperative appearance was satisfactory.

Topics: Adolescent; Adult; Artificial Organs; Bacterial Infections; Child; Child, Preschool; Chondroitin Sulfates; Collagen; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Nevus; Silicones; Skin; Skin Neoplasms; Skin Transplantation; Surgical Flaps